| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 275, Issue 25, 19035-19040, June 23, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, February 4, 2000, and in revised form, April 11, 2000
We previously reported that expression of
polyglutamine-expanded huntingtin induces apoptosis via c-Jun
amino-terminal kinase (JNK) activation in HN33 cells (Liu, Y. F. (1998) J. Biol. Chem. 273, 28873-28822). Extending
this study, we now demonstrate a role of mixed-lineage kinase 2 (MLK2),
a JNK activator, in polyglutamine-expanded huntingtin-mediated neuronal
toxicity. We find that normal huntingtin interacts with MLK2, whereas
the polyglutamine expansion interferes with this interaction. Similar
to the expression of polyglutamine-expanded huntingtin, expression of
MLK2 also induces JNK activation and apoptosis in HN33 cells.
Co-expression of dominant negative MLK2 significantly attenuates
neuronal apoptosis induced by the mutated huntingtin. Furthermore,
over-expression of the N terminus of normal huntingtin partially
rescues the neuronal toxicity induced by MLK2. Our results suggest that
activation of MLK2-mediated signaling cascades may be partially
involved in neuronal death induced by polyglutamine-expanded huntingtin.
Huntington's disease
(HD)1 is a neurodegenerative
disorder with dominant inheritance (2). The disease is characterized by choreiform movement, mental impairment, and cognitive symptoms (3, 4).
The HD gene encodes a 350-kDa protein designated as huntingtin (2),
which is ubiquitously expressed with the highest levels being found in
the brain, lung, and testes (5, 6). Immunocytochemistry reveals that in
neurons huntingtin is a cytoplasmic protein found in cell bodies,
dendrites, and also in nerve terminals, where huntingtin is associated
with synaptic vesicles and microtubule complexes (6, 7). The defect in the HD gene causes an expansion of a polyglutamine stretch near the N
terminus of huntingtin, and the length of the polyglutamine repeat is
correlated with the age of onset and the severity of the disease (8).
To date, the normal function of huntingtin remains to be determined,
and the molecular mechanism underlying neuronal death in HD is poorly understood.
In previous studies, we found that expression of polyglutamine-expanded
huntingtin caused neuronal apoptosis via activation of JNKs in HN33
cells, a hippocampal neuron-derived cell line (1). The aim of the
present study was to investigate the molecular mechanism by which
polyglutamine-expanded huntingtin activates JNKs and induces neuronal
apoptosis. Huntingtin contains multiple proline-rich motifs that may
bind to both SH3 and WW domain-containing proteins (9). Interestingly,
the N-terminal proline-rich region, which is about 40 amino acids long,
is adjacent to the polyglutamine stretch. This proline-rich region has
been shown to bind to both SH3 and WW domain-containing proteins
(10-12). MLK2 is a member of the mixed-lineage kinase family whose
kinase domain shows structural features of both tyrosine-specific and
serine/threonine-specific protein kinases (13). MLK2 possesses an SH3
domain that is homologous to the SH3 domains of Grb2 (13). MLK2 is
predominantly expressed in the brain (13), and it has been reported
that MLK2 can directly bind and mediate activation of MKK7 and SEK1,
which in turn induces JNK activation (14-19). At moderate expression
levels, MLK2 appears to selectively activate JNKs and has little effect
on other mitogen-activated protein kinases (14-16). Thus, MLK2 is a
potential candidate for the involvement in JNK activation and neuronal
toxicity induced by polyglutamine-expanded huntingtin. The current
study was undertaken to investigate the role of MLK2 in mutated
huntingtin-mediated neuronal toxicity. Our results suggest that
huntingtin binds to the SH3 domain of MLK2 and the polyglutamine
expansion interferes with its binding to the kinase. Activation of
MLK2-mediated signal transduction pathways may be involved in
initiating neuronal death in HD.
Cell Culture and Transient Transfection--
HN33 cells, an
immortalized rat hippocampal neuronal cell line (1), and 293T cells,
human embryonic kidney cells expressing SV40 large T antigen, were
maintained in Dulbecco's modified Eagle's medium/F12 medium
supplemented with 10% fetal bovine serum on 10-cm plates. HN33 or 293T
cells at 50 to 60% confluence were washed once with serum-free medium
prior to transfection. Transfection was performed using Lipofectin
(Life Technologies, Inc.) according to manufacturer instructions.
10-50 µg of plasmid with 10-20 µl of Lipofectin/10-cm plate was
used in transfection experiments.
Western Blotting and Immunoprecipitation--
48-72 h after
transfection, 293T cells were harvested and lysed in 1% Nonidet P-40
lysis buffer, and co-immunoprecipitation experiments were conducted as
described previously using an anti-huntingtin's N terminus antibody
437 (10) or anti-c-Myc-tagged antibody 9E10 (Santa Cruz). Human brain
tissues were obtained from Dr. J.-P. Vonsattel or Human Brain Bank at
McLean Hospital, Boston, MA with institutional review board approval.
Post-mortem time was between 10-12 h. The diagnosis of HD was
confirmed with neuropathological and genetic phenotype analysis. Human
cortex tissues from normal subjects or HD patients were homogenized in
detergent-free lysis buffer, and Nonidet P-40 was added to a final
concentration of 1%. The mixture was then incubated at 4 °C with
constant shaking for 1-2 h, and insoluble fractions were removed by centrifugation.
Purification of GST Fusion Proteins and in Vitro Binding
Assay--
Huntingtin N-terminal GST fusion protein constructs were
generated by subcloning of a cDNA fragment encoding the first three exons of the HD gene containing 16 or 56 CAG repeats into pGEX2T. Construct for MLK2 C terminus (amino acids 407-953) GST fusion proteins was a generous gift of Dr. Alan Hall (University College London, London, UK) (14). The MLK2 SH3 domain cDNA fragment was
amplified by reverse transcription-PCR and inserted into pGEX4T1. To
generate MLK2 SH3-deficient GST fusion proteins, substitution of the
first tryptophan at position 58 of the highly conserved tryptophan
doublet of the SH3 domain to lysine was achieved by overlapping
extension using PCR with mutated oligonucleotides. Such a substitution
eliminates the ability of SH3 domains to bind to proline-rich ligands
(10). Expression and purification of different MLK2 or huntingtin GST
fusion proteins was performed as described previously, and ~0.1 µg
of GST fusion protein was used for in vitro binding studies.
Subcloning and Mutagenesis--
The full-length c-Myc-tagged
MLK2 was a gift from Dr. Alan Hall (14). A kinase-dead version of MLK2
was generated by introduction of an Ala-Gly point mutation at position
651 (codon AAG to GAG) by overlapping PCR extension with mutated
oligonucleotides, to result in an amino acid substitution of Lys to Glu
at the ATP binding loop of the kinase domain. To generate an expression
vector for huntingtin's N terminus with 16 CAG repeats, a cDNA
fragment was excised from pFL16HD with NotI and
SphI and subcloned into pcDNA 1.1 (Invitrogen).
JNK and TUNEL Assays--
16 h after transfection, HN33 cells
were lysed with 1% Triton X-100 lysis buffer (1). JNK was assayed as
described previously (1). For TUNEL assay, HN33 cells were plated on a
slide culture chamber. After transfection, cells were fixed at the time
indicated in the figures, and TUNEL staining was performed as described previously (1). Most apoptotic HN33 cells were detached from the
slides, and TUNEL stain was performed on remaining attached cells.
TUNEL stain-negative cells (living cells) were counted in the 20×
power field in four different locations on the slides and ~600-800
cells were counted in the control (1).
293T cells, which are rich in huntingtin (10), were utilized to
study the interaction of huntingtin with MLK2. c-Myc-tagged MLK2 was
transiently expressed in 293T cells, and cell lysates were
immunoprecipitated with 437, an anti-huntingtin N-terminal antibody
(10), and the resulting blot was probed with 9E10, an anti-c-Myc-tagged
monoclonal antibody. MLK2 was detected in 437 and 9E10
immunoprecipitates of lysates transfected with c-Myc-tagged MLK2 but
not in the negative controls, 9E10 or 437 immunoprecipitates of
wild-type or vector-transfected 293T cell lysates (Fig.
1A). Conversely, we also found
that huntingtin protein was present in 9E10 immunoprecipitates of
c-Myc-tagged MLK2-transfected 293T cell lysates but not wild-type or
vector-transfected lysates (Fig. 1B). These data show that
MLK2 is associated with huntingtin in intact cells.
Next, we examined the interaction of MLK2 with huntingtin in a
hippocampal neuronal cell line, HN33 cells in which we found that
expression of polyglutamine-expanded huntingtin induced apoptosis (1).
MLK2 is richly expressed in HN33 cells, and the amount of MLK2 proteins
in the cell is similar to that of 293T cells over-expressing
c-Myc-tagged MLK2 (Fig. 1C). HN33 cell lysates were
immunoprecipitated with 437 or 4C8, a well characterized anti-huntingtin monoclonal antibody (5), and the resulting blot was
probed with a specific anti-MLK2 antibody that has been characterized
previously (20). As shown in Fig.
2B, both 437 and 4C8 were able
to precipitate MLK2 from HN33 cell lysates, whereas the peptide-antigen
pre-absorbed 437 failed to do so. These data provide further evidence
that normal huntingtin is associated with MLK2 in neuronal cells.
Activation of MLK2-mediated Signaling Cascades by
Polyglutamine-expanded Huntingtin*
§,
Department of Pharmaceutical Sciences,
Northeastern University, Boston, Massachusetts 02115, ¶ Trecowthick Research Center, Peter MacCallum Cancer Institute,
Melbourne, Victoria 3000, Australia, and Department of Molecular
Pharmacology, Physiology and Biotechnology, Brown University,
Providence, Rhode Island 02912
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
View larger version (40K):
[in a new window]
Fig. 1.
The association of normal huntingtin with
MLK2. All data presented are from a typical experiment that has
been repeated twice with similar results. A, detection of
MLK2 in huntingtin immunoprecipitates was as follows: 293T cell lysates
of wild-type (437IPC and 9E10IPC) or transfected
with pRK5 vector alone (9E10IPV) or c-Myc-tagged MLK2
(437IPT and 9E10IPT) were incubated with 9E10 or
437, and the blot was analyzed by 9E10. B, detection of
huntingtin in MLK2 immunoprecipitates was as follows: 293T cell lysates
of wild-type (9E10IPC) or transfected with vector alone
(9E10IPV) or c-Myc-tagged MLK2 (9E10IPT) were
incubated with 9E10, and the blot was analyzed by 4C8 (3). 437 immunoprecipitation (HDPIP) was a positive control.
HDP, huntingtin. C, detection of endogenously
expressed MLK2 in huntingtin immunoprecipitates was as follows: HN33
cell lysates were incubated with 437 or 4C8, and the blot was analyzed
by an anti-MLK2 antibody characterized previously (36).
437IP, IP with 437; P437IP, IP with
peptide-antigen preabsorbed 437; 4C8IP, IP with 4C8.
D, the SH3 domain of MLK2 mediated its interaction with
huntingtin as follows: GST alone or GST fusion proteins of MLK2-SH3
domain (MLK2-SH3), MLK2-C terminus (MLK2C-T.), or
MLK2-deficient SH3 domain (MLK2-mSH3) were incubated with
293T cell lysates, and the blot was analyzed by 437.
View larger version (27K):
[in a new window]
Fig. 2.
The polyglutamine expansion interferes with
huntingtin to bind to the SH3 domain of MLK2. All data presented
are from a typical experiment that has been repeated at least three
times with similar results. A, the polyglutamine expansion
inhibits huntingtin's N terminus to bind to MLK2; 293T cell lysates
transfected with c-Myc-tagged MLK2 were incubated with GST alone or
huntingtin's N terminus GST fusion proteins containing 16 (16CAG) or 56 (56CAG) polyglutamine repeats, and
the blot was analyzed by 9E10 (9E10IP). B, the
ability of the mutated huntingtin to bind to the SH3 domain of MLK2 is
impaired. Human cortex lysates from a normal subject and an HD patient
were incubated with GST alone or GST fusion proteins of MLK2-SH3 domain
(MLKSH3) or MLK2-deficient SH3 domain (MLKmSH3),
and the blot was analyzed by 437. N. lys or N.,
normal human cortex lysates; HD. lys or H., HD
patient's cortex lysates.
To determine whether the SH3 domain of MLK2 mediates its interaction with huntingtin, we investigated the binding of huntingtin to a GST MLK2-SH3 domain fusion protein, whereas a GST MLK2 C terminus fusion protein, which lacks the SH3 domain, served as a negative control. As shown in Fig. 1D, huntingtin binds to the MLK2 SH3 domain but not GST alone or the MLK2 C terminus. To verify whether the SH3 domain of MLK2 mediates its interaction with huntingtin, we generated a MLK2-SH3 domain-deficient GST fusion protein by substitution of the first tryptophan of the highly conserved tryptophan doublet of the MLK2 SH3 domain to lysine. Mutation of the tryptophan doublet of the SH3 domain is known to eliminate its ability to bind to proline-rich ligands (10). Huntingtin failed to bind to MLK2-SH3 domain-deficient GST fusion proteins (Fig. 1D). These data show that the SH3 domain of MLK2 mediates its interaction with normal huntingtin.
We next determined whether expansion of the polyglutamine repeat in huntingtin would alter its interaction with MLK2. The N-terminal proline-rich region adjacent to the polyglutamine repeat has been reported to bind to SH3 domain-containing proteins (10-11). Thus, we examined the binding of MLK2 to huntingtin's N terminus containing either a normal or expanded polyglutamine stretch. GST fusion proteins of huntingtin's N terminus containing 16 or 56 polyglutamine repeats were generated and purified. These GST fusion proteins were utilized as a template to examine whether huntingtin's N terminus is responsible for its interaction with MLK2 and how expansion of the polyglutamine repeat affects this interaction. As shown in Fig. 2A, MLK2 binds to huntingtin's N terminus containing 16 polyglutamine repeats. Because the N-terminal proline region is the only potential SH3 domain binding site in this small N-terminal segment of huntingtin and others have shown that this region mediates huntingtin binding to SH3 domain (11), these data suggest that the N-terminal proline region is involved in huntingtin interaction with MLK2. The amount of c-Myc-tagged MLK2 bound to huntingtin's N terminus with 56 polyglutamine repeats was significantly reduced, about 70% less than that associated with the N terminus of normal huntingtin (Fig. 2A). This data indicates that expansion of the polyglutamine repeat may inhibit the ability of huntingtin's N terminus to interact with the SH3 domain of MLK2.
Next, we examined the interaction of MLK2 with huntingtin in the human brain. Because our MLK2 antibody cannot be used for immunoprecipitation, a MLK2 SH3 domain GST fusion protein was used to test the ability of normal and polyglutamine-expanded huntingtin proteins from human brain tissues to bind to MLK2. Lysates of human brain cortex tissues from a normal subject and a mid-age onset HD patient were prepared. Wild-type or mutated MLK2 SH3 domain GST fusion protein was incubated with human brain lysates, and the resulting blot was probed with 437. As shown in Fig. 2B, normal huntingtin protein from normal or HD human cortex tissues bound to the wild-type MLK2 SH3 GST fusion protein but not to GST alone or to the MLK2 SH3 domain-deficient GST fusion protein. In contrast, polyglutamine-expanded huntingtin protein from the HD patient brain only weakly bound to the SH3 domain of MLK2 (Fig. 2B). These data further support our findings that normal huntingtin binds to the SH3 domain of MLK2 and that the polyglutamine expansion interferes with its ability to interact with the SH3 domain of the kinase.
MLK2 is known to induce JNK activation in Cos-1 cells (14). Therefore,
we tested whether expression of MLK2 activates JNKs in HN33 cells. The
MLK2 expression vector (pRK5) or vector alone was transiently
transfected into HN33 cells. JNKs were precipitated using a GST·c-Jun
protein, and an in vitro JNK assay was performed. An equal
amount of JNK proteins were precipitated in each JNK assay (data not
shown). As observed in other neuronal cells (21), a basal level of JNK
activity was found in HN33 cells (Fig.
3A). MLK2 induced constitutive
activation of JNKs in HN33 cells. As shown in Fig. 3A, the
level of the JNK activity was increased by 8-fold (Fig. 3, A
and B). Because MLK2 mediates JNK activation via
phosphorylation and activation of both MKK7 and SEK1 (14-16), we
determined whether co-expression of dominant negative MKK7 and SEK1
could block MLK2-mediated JNK activation. As shown in Fig.
3A, MLK2-mediated JNK activation was significantly
attenuated by co-expression of dominant negative MKK7 and SEK1 but not
by co-expression of wild-type MKK7 and SEK1, which had little effect on
the JNK activity induced by MLK2 (Fig. 3, A and
B). Co-expression of wild-type MKK7 and SEK1 did not
significantly alter basal JNK activity in HN33 cells (Fig. 3,
A and B), whereas co-expression of dominant
negative MKK7 and SEK1 inhibited basal JNK activity, which is toxic to
HN33 cells (see below Fig. 3D).
|
We have reported that expression of polyglutamine-expanded huntingtin induces neuronal apoptosis by activation of JNKs in HN33 cells (1). Because MLK2 also activates JNKs in HN33 cells, we examined whether expression of MLK2 induced neuronal toxicity in HN33 cells. Vector alone or c-Myc-tagged MLK2 was transiently expressed in HN33 cells and, 24 and 48 h post-transfection, cells were fixed and Tdt-mediated dUTP-biotin nick end labeling (TUNEL) staining, which detects the late stage of apoptosis, was conducted. TUNEL-negative cells (living cells) were counted. Expression of MLK2 induced rapid apoptotic cell death in HN33 cells (Fig. 3C). HN33 cells started to undergo apoptosis at ~24 h post-transfection (Fig. 3C). At 48 h post-transfection, most HN33 cells were detached from the plate (apoptotic), and remaining attached cells were also apoptotic (Fig. 3C). Similar to expression of polyglutamine-expanded huntingtin (1), expression of MLK2 not only led to neuronal death of transfected HN33 cells but also mediated cell toxicity of non-transfected HN33 cells, suggesting that activation of MLK2 may cause the release of cellular diffusible factors that are toxic to neighboring neuronal cells (1).
Next, we investigated whether co-expression of dominant negative MKK7 and SEK1 would inhibit MLK2-mediated neuronal toxicity. Expression of wild-type or dominant negative mutant forms of MKK7 or SEK1 alone did not alter cell viability (1). Co-expression of wild-type SEK1 and MKK7 also did not generate any cell toxicity (Fig. 3D), whereas co-expression of dominant negative SEK1 and MKK7 significantly attenuated neuronal toxicity induced by MLK2. As shown in Fig. 3D, ~75% of HN33 cells were rescued upon co-expression of the dominant negative mutant form of MKK7 and SEK1. These data indicate that JNK-mediated neuronal toxicity is induced by MLK2 in HN33 cells. Co-expression of dominant negative MKK7 and SEK1 without MLK2 caused rapid apoptosis in HN33 cells (Fig. 3D). Inhibition of basal JNK activity may account for this cell toxicity, because co-expression of dominant negative MKK7 and SEK1 decreased basal JNK activity in HN33 cells (Fig. 3, A and B), whereas when these two mutated kinases were co-expressed with MLK2 in HN33 cells, JNK activity was double the basal level (Fig. 3, A and B), and under this condition HN33 cells were viable (Fig. 3D). These results suggest that a certain basal level of JNK activity appears to be essential for the survival of HN33 cells, and either over-activation or inhibition of basal JNK activity triggers apoptosis.
To further investigate whether MLK2-mediated signaling cascades are
involved in neuronal death induced by polyglutamine-expanded huntingtin, a dominant negative (kinase-dead) form of MLK2, which is
known to competitively inhibit the endogenous kinase, was generated. Different full-length huntingtin expression vectors containing 16, 48, or 89 polyglutamine repeats were separately co-transfected with
wild-type or the dominant negative form of MLK2 into HN33 cells. As
shown in Fig. 4A,
co-expression of dominant negative MLK2 significantly inhibited
neuronal toxicity mediated by polyglutamine-expanded huntingtin in HN33
cells. At 48 h post-transfection of the huntingtin construct
containing 48 or 89 CAG repeats, over 75% of HN33 cells remained
viable (i.e. trypan blue stain-negative) when dominant negative MLK2 is co-expressed, compared with 70-80% of apoptotic cells when the mutated huntingtin was expressed alone (Fig.
4A). These data further support a role for MLK2 in the
mediation of neuronal toxicity induced by polyglutamine-expanded
huntingtin.
|
Our data show that the N-terminal proline-rich region of huntingtin
interacts with MLK2, and the polyglutamine expansion interferes with
this interaction. These results suggest that the polyglutamine expansion may lead to an increase in free MLK2 proteins, which are
constitutively active and cell toxic (14). If this hypothesis is true,
over-expression of the N terminus of normal huntingtin, which binds to
free MLK2 proteins, should be able to overcome the neuronal toxicity
induced by MLK2 and polyglutamine-expanded huntingtin. We prepared a
construct encoding a small region of the normal huntingtin N terminus,
containing a 16 polyglutamine repeat and the proline-rich region. As
shown in Fig. 4B, co-expression of this N-terminal fragment
of normal huntingtin significantly attenuated neuronal toxicity
mediated by MLK2 and by the mutated huntingtin with 48 polyglutamine
repeats. Over 50% of neurons remained viable at 48 h
post-transfection, compared with less than 20% of viable cells when
the N-terminal fragment was not co-expressed (Fig. 4B).
These studies support our hypothesis that the polyglutamine expansion
in huntingtin may interfere with its interaction with MLK2 thereby
leading to an increase of free MLK2 proteins that in turn mediate JNK
activation and neuronal apoptosis.
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
In the present study, we demonstrate that MLK2, an upstream activator of the JNK pathway, is involved in JNK activation and neuronal apoptosis mediated by polyglutamine-expanded huntingtin (1). The polyglutamine expansion decreases the association of huntingtin with MLK2 leading to an increase in unregulated MLK2 proteins that, being constitutively active, cause JNK activation and neuronal toxicity. Co-expression of dominant negative MKK7 and SEK1, the downstream effectors of MLK2, blocks JNK activation and neuronal apoptosis induced by MLK2 and by polyglutamine-expanded huntingtin. Additionally, co-expression of dominant negative MLK2 significantly attenuated JNK activation and neuronal toxicity mediated by the polyglutamine expanded huntingtin. Finally, over-expression of a normal huntingtin N-terminal protein significantly attenuated neuronal toxicity induced by both MLK2 and polyglutamine-expanded huntingtin. These results show that MLK2-mediated cellular signaling cascades may play a significant role in neuronal death induced by polyglutamine-expanded huntingtin in HN33 cells.
Because huntingtin is a ubiquitously expressed protein, whereas the pathology of HD is restricted to the brain, it is likely that huntingtin binds to proteins that are largely found in the brain, and the polyglutamine expansion alters huntingtin's ability to interact with these proteins thereby resulting in activation of neurotoxic pathways. MLK2 being almost exclusively expressed in the brain could provide a partial explanation for why the polyglutamine-expanded huntingtin is selectively toxic to neurons. MLK2 is a strong activator of the JNK pathway that is now known to couple a variety of cell-toxic stimuli, leading to neuronal apoptosis (21, 22). Because MLK2 is a constitutively active kinase, and free MLK2 is the active form (14), any alteration of the amount of bound MLK2 is likely to lead to activation of MLK2-mediated signaling cascades and neuronal toxicity. We show that normal huntingtin proteins from normal or HD human cortex tissues specifically bind to wild-type but not the mutated SH3 domain of MLK2, and under the same conditions, the mutated huntingtin proteins from HD patient cortex tissues only weakly bound to the SH3 domain of MLK2. Moreover, over-expression of the N terminus of normal huntingtin, which binds and decreases free MLK2 proteins in HN33 cells, can significantly inhibit neuronal toxicity induced by MLK2 and by the mutated huntingtin, further supporting the notion that huntingtin's N terminus interacts with the SH3 domain of MLK2, and the ability to bind to the kinase may be impaired upon polyglutamine expansion in huntingtin.
The polyglutamine expansion apparently alters the physical properties of huntingtin. The mobility of the mutated huntingtin on SDS-polyacrylamide gel electrophoresis is clearly decreased (5), and huntingtin's N terminus protein carrying an expanded polyglutamine stretch forms amyloid-like protein aggregates both in vitro and in vivo (23, 24). Because the N-terminal proline-rich region is adjacent to the polyglutamine stretch, it is possible that the polyglutamine expansion may alter the binding properties of this proline-rich region. Our group previously found that normal huntingtin is associated with epidermal growth factor receptor signaling complexes through binding to the SH3 domains of Grb2 and RasGAP, and this association is regulated by activation of the epidermal growth factor receptor (10). Recently, other groups have also reported that huntingtin binds to Grb2-like SH3 domain-containing proteins, and the N-terminal proline-rich region mediates these interactions (10-11). Our results from the current study are consistent with these reports (10-11). In addition, we show that the ability of this proline-rich region to bind to the SH3 domain of MLK2 is impaired upon expansion of the polyglutamine stretch. The interaction of proline-rich motifs with SH3 domains is not a highly selective event (9). Thus, if the polyglutamine expansion in huntingtin interferes with its interaction with the SH3 domain of MLK2, it may inhibit its association with other SH3 domain-containing proteins. Perhaps the normal function of huntingtin is the modulation of the cellular signaling network by sequestering these SH3 domain-containing signaling proteins. When the ability of huntingtin to interact with SH3 domains is impaired, polyglutamine-expanded huntingtin may be disassociated from the microtubule complex where most SH3 domain-containing proteins are found, leading to the re-arrangement of SH3 domain-containing protein-associated signaling complexes, which may subsequently result in an imbalance of cellular signaling networks and neuronal death. Incidentally, huntingtin's N terminus with an expanded length of polyglutamine repeat forms nuclear inclusions in the brains of HD patients or in cultured cells (25), indicating that some mutated huntingtin proteins are translocated and no longer co-present with MLK2 or other SH3 domain-containing proteins in the cytoplasm.
It is clear now that striatal medium-spiny neurons, which die first in
HD, lack endogenous huntingtin. Thus, diffusible neurotoxic factors may
play an important role in early neuronal loss in HD. Our previous
studies and current results are consistent with this notion; expression
of the mutated huntingtin or MLK2 induces not only apoptotic cell death
of transfected HN33 cells but also non-transfected cells. Because JNK
activation has been reported to mediate free radical production (26),
it is possible that polyglutamine-expanded huntingtin may mediate free
radical production via activation of the MLK2-JNK pathway. In summary,
our current studies show that activation of MLK2-mediated signaling
cascades may be partially responsible for neuronal loss in HD, and an
inhibitor of MLK2 may be useful for the prevention of neuronal loss in
HD.
| |
ACKNOWLEDGEMENT |
|---|
We thank Drs. Y.-R. Liu and R. Deth for generous support and Drs. R. Deth, J. Freedman, E. Garcia, and L. Blair for critical reading of and helpful comments on the manuscript. We express our gratitude to Dr. A. Hall for MLK2 constructs, Drs. D. Tangle and P. H. Reddy for huntingtin's N terminus GST fusion proteins, and Dr. R. Davis for wild-type and dominant negative MKK7 constructs.
| |
FOOTNOTES |
|---|
* This work is supported in part by United States Army Medical Research and Materiel Command.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
This work is dedicated to Dr. R.-Y. Zhong.
§ To whom correspondence should be addressed: Dept. of Pharmaceutical Sciences, Northeastern University, 312 Mugar Hall, 360 Huntington Ave., Boston, MA 02115. Tel.: 617-373-3904; Fax: 617-373-8886; E-mail: yafliu@lynx.neu.edu.
Published, JBC Papers in Press, May 3, 2000, DOI 10.1074/jbc.C000180200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: HD, Huntington's disease; MLK2, mixed lineage kinase 2; JNK(s), c-Jun amino-terminal kinase(s); MKK7, mitogen-activated protein kinase 7; SEK1, stress-signaling kinase 1; PCR, polymerase chain reaction; GST, glutathione S-transferase; TUNEL, Tdt-mediated dUTP-biotin nick end labeling; IP, immunoprecipitation.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
| 1. | Liu, Y. F. (1998) J. Biol. Chem. 273, 28873-28877 |
| 2. | Huntington's Disease Collaborative Research Group. (1993) Cell 72, 971-983 |
| 3. | Martin, J. B., and Gusella, J. F. (1986) N. Engl. J. Med. 315, 1267-1276 |
| 4. | Ferrante, R. J., Kowall, N. W., Beal, M. F., Richardson, E. P., Jr., Bird, E. D., and Martin, J. B. (1985) Science 230, 561-563 |
| 5. | Trottier, Y., Devys, D., Imbert, G., Saudou, F., An, I., Lutz, Y., Weber, C., Agid, Y., Hirsch, E. C., and Mandel, J. L. (1995) Nat. Genet. 10, 104-110 |
| 6. | Fusco, F. R., Chen, Q., Lamoreaux, W., Figueredo-Cardenas, G., Jiao, Y., Coffiman, J. A., Surmerier, D. J., Honig, M. G., Carlock, L. R., and Reiner, A. (1999) J. Neurosci. 19, 1189-1202 |
| 7. | Gutekunst, C.-A., Levey, A. J., Hellman, C. J., Whsley, W. L., Yi, H., Nash, R., Rees, H. D., Madden, J. J., and Hersch, S. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8710-8714 |
| 8. | Stine, O. C., Pleasant, N., Franz, M. L., Abbott, M. H., Folstein, S. E., and Ross, C. A. (1993) Hum. Mol. Genet. 2, 1547-1549 |
| 9. | Sudol, M. (1998) Oncogene 17, 1469-1474 |
| 10. | Liu, Y. F., Deth, R. C., and Devys, D. (1997) J. Biol. Chem. 272, 8121-8124 |
| 11. | Sitter, A., Wälter, S., Wedemeyer, N., Hasenbank, R., Scherzinger, E., Eickhoff, H., Bates, G. P., Lehrach, H., and Wanker, E. E. (1998) Mol. Cell 2, 427-436 |
| 12. | Faber, P. W., Barnes, G. T., Srinidhi, J., Chen, J., Gusella, J. F., and MacDonald, M. E. (1998) Hum. Mol. Genet. 7, 1463-1474 |
| 13. | Dorow, D. S., Devereux, L., Tu, G.-F., Price, G., Nicholl, J. K., Sutherland, G. R., and Simpson, R. J. (1995) Eur. J. Biochem. 234, 492-500 |
| 14. | Nagata, K., Puls, A., Futter, C., Aspenstrom, P., Schaefer, E., Nakata, T., Hirokawa, N., and Hall, A. (1998) EMBO J. 17, 149-158 |
| 15. | Hirai, S., Katoh, M., Terada, M., Kyriakis, J. M., Zon, L. I., Rana, A., Avruch, J., and Ohno, S. (1997) J. Biol. Chem. 272, 15167-15173 |
| 16. | Hirai, S., Noda, K., Moriguchi, T., Nishida, E, Yamashita, A., Deyama, T., Fukuyama, K., and Ohno, S. (1998) J. Biol. Chem. 273, 7406-7412 |
| 17. | Gupta, S., Campbell, D., Derijard, B., and Davis, R. J (1995) Science 267, 389-393 |
| 18. | Sanchez, I., Hughes, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M., and Zon, L. I. (1994) Nature 380, 75-79 |
| 19. | Tournier, C., Whitmarsh, A. J., Cavanagh, J., Barrett, T., and Davis, R. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 84, 7337-7342 |
| 20. | Phelan, D. R., Loveland, K. L., Devereux, L., and Dorow, D. S. (1999) Mol. Reprod. Dev. 52, 135-140 |
| 21. | Schwarzschild, M. A., Cole, R. L., and Hyman, S. E. (1997) J. Neurosci. 17, 3455-3466 |
| 22. | Eilers, A., Whitfield, J., Banij, C., Rubin, L. L., and Ham, J. (1998) J. Neurosci. 18, 1713-1724 |
| 23. | DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. P., Bates, G. P., Vonsattel, J. P., and Aronin, N. (1997) Science 277, 1990-1993 |
| 24. | Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., and Wanker, E. E. (1997) Cell 90, 549-559 |
| 25. | Saudou, F., Finkbeiner, S., Deys, D., and Greenberg, M. E. (1998) Cell 95, 55-66 |
| 26. | Go, Y. M., Patel, R. P., Maland, M. C., Park, H., Beckman, J. S., Darley-Usmar, V. M., and Jo, H. (1999) Am. J. Physiol. 277, H1647-H1653 |
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Scappini, T.-W. Koh, N. P. Martin, and J. P. O'Bryan Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase Hum. Mol. Genet., August 1, 2007; 16(15): 1862 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N.T. Strehlow, J. Z. Li, and R. M. Myers Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space Hum. Mol. Genet., February 15, 2007; 16(4): 391 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Schachter, Y. Du, A. Lin, and K. A. Gallo Dynamic Positive Feedback Phosphorylation of Mixed Lineage Kinase 3 by JNK Reversibly Regulates Its Distribution to Triton-soluble Domains J. Biol. Chem., July 14, 2006; 281(28): 19134 - 19144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Apostol, K. Illes, J. Pallos, L. Bodai, J. Wu, A. Strand, E. S. Schweitzer, J. M. Olson, A. Kazantsev, J. L. Marsh, et al. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity Hum. Mol. Genet., January 15, 2006; 15(2): 273 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Novak and A. N. Jain Pathway recognition and augmentation by computational analysis of microarray expression data Bioinformatics, January 15, 2006; 22(2): 233 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Charvin, P. Vanhoutte, C. Pages, E. Borrelli, and J. Caboche Unraveling a role for dopamine in Huntington's disease: The dual role of reactive oxygen species and D2 receptor stimulation PNAS, August 23, 2005; 102(34): 12218 - 12223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Marcora, K. Gowan, and J. E. Lee Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2 PNAS, August 5, 2003; 100(16): 9578 - 9583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Holbert, A. Dedeoglu, S. Humbert, F. Saudou, R. J. Ferrante, and C. Neri Cdc42-interacting protein 4 binds to huntingtin: Neuropathologic and biological evidence for a role in Huntington's disease PNAS, March 4, 2003; 100(5): 2712 - 2717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Akbarzadeh, H. Ji, D. Frecklington, N. Marmy-Conus, Y.-F. Mok, L. Bowes, L. Devereux, M. Linsenmeyer, R. J. Simpson, and D. S. Dorow Mixed Lineage Kinase 2 Interacts with Clathrin and Influences Clathrin-coated Vesicle Trafficking J. Biol. Chem., September 20, 2002; 277(39): 36280 - 36287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Garcia, P. Vanhoutte, C. Pages, M.-J. Besson, E. Brouillet, and J. Caboche The Mitochondrial Toxin 3-Nitropropionic Acid Induces Striatal Neurodegeneration via a c-Jun N-Terminal Kinase/c-Jun Module J. Neurosci., March 15, 2002; 22(6): 2174 - 2184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Song, G. Perides, and Y. F. Liu Expression of Full-length Polyglutamine-expanded Huntingtin Disrupts Growth Factor Receptor Signaling in Rat Pheochromocytoma (PC12) Cells J. Biol. Chem., February 15, 2002; 277(8): 6703 - 6707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Davies and D B Ramsden Huntington's disease Mol. Pathol., December 1, 2001; 54(6): 409 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Cummings, Y. Sun, P. Opal, B. Antalffy, R. Mestril, H. T. Orr, W. H. Dillmann, and H. Y. Zoghbi Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice Hum. Mol. Genet., July 1, 2001; 10(14): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Holbert, I. Denghien, T. Kiechle, A. Rosenblatt, C. Wellington, M. R. Hayden, R. L. Margolis, C. A. Ross, J. Dausset, R. J. Ferrante, et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis PNAS, January 24, 2001; (2001) 41566798. [Abstract] [Full Text]
|
|
|
|
|
|
M. F. Peters and C. A. Ross Isolation of a 40-kDa Huntingtin-associated Protein J. Biol. Chem., January 26, 2001; 276(5): 3188 - 3194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Phelan, G. Price, Y. F. Liu, and D. S. Dorow Activated JNK Phosphorylates the C-terminal Domain of MLK2 That Is Required for MLK2-induced Apoptosis J. Biol. Chem., March 30, 2001; 276(14): 10801 - 10810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Maroney, J. P. Finn, T. J. Connors, J. T. Durkin, T. Angeles, G. Gessner, Z. Xu, S. L. Meyer, M. J. Savage, L. A. Greene, et al. CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family J. Biol. Chem., June 29, 2001; 276(27): 25302 - 25308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Savinainen, E. P. Garcia, D. Dorow, J. Marshall, and Y. F. Liu Kainate Receptor Activation Induces Mixed Lineage Kinase-mediated Cellular Signaling Cascades via Post-synaptic Density Protein 95 J. Biol. Chem., March 30, 2001; 276(14): 11382 - 11386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sun, A. Savanenin, P. H. Reddy, and Y. F. Liu Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-D-aspartate Receptors via Post-synaptic Density 95 J. Biol. Chem., June 29, 2001; 276(27): 24713 - 24718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Holbert, I. Denghien, T. Kiechle, A. Rosenblatt, C. Wellington, M. R. Hayden, R. L. Margolis, C. A. Ross, J. Dausset, R. J. Ferrante, et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis PNAS, February 13, 2001; 98(4): 1811 - 1816. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||
